New data show high diagnostic performance for ovarian, endometrial, and cervical cancers, with a targeted assay designed to run on existing clinical laboratory equipment.
Self-collection for HPV and other infections offers a more convenient, private way to complete recommended screenings—helping reach women who might otherwise delay or skip care.
There are significant barriers to cervical cancer screening. Sample self-collection promises to improve access to testing and treatment.
In this episode of Clinical Lab Chat, Jeff Andrews, MD, FRCSC, of BD, returns to discuss BD and MD Anderson’s HPV self-collection study.
Read More
A first-of-its-kind HPV self-collection pilot program has launched in Texas to improve cervical cancer screening access in underserved areas.
Read More
Labcorp’s adoption of artificial intelligence technology aims to enhance the screening process for cervical cancer.
Read More
A new study reveals that 85% of women would welcome the option to choose between self-sampling and nurse-led HPV cervical screening.
Read More
In this episode of Clinical Lab Chat, we discuss what sample self-collection means for the diagnosis and treatment of HPV and cervical cancer.
Read More
BD is shipping its FDA-approved HPV self-collection kits to healthcare facilities, offering an accessible cervical cancer screening option.
Read More
A new study has identified specific biomarkers in cervical mucus that could improve accuracy in the early detection of cervical cancer.
Read More
Seegene demonstrated its new HPV diagnostic products and emphasized the importance of HPV screening at the AOGIN conference.
Read More
Researchers developed a urine test using ELISA to detect HPV16 E7 oncoproteins, a noninvasive method for cervical cancer screening.
Read More
A new study highlights support among healthcare providers for HPV self-collection, which could improve access to cervical cancer screening.
Read More
Researchers developed an effective cervical cancer screening method, which detects more cancers and precancerous stages than current methods.
Read More
BD received FDA approval for women to self-collect vaginal specimens for HPV testing, expanding access to cervical cancer screening.
Read More
che received FDA approval for its HPV self-collection solution, allowing individuals to collect their own samples.
Read More
An at-home cervical cancer screening device received Breakthrough Device status to help increase testing access for people in need.
Read More
Researchers developed a urine-based test utilizing whole genome sequencing to detect DNA fragments released by head and neck tumors.
Read More